Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitolisant for EDS in OSA (HAROSA IV)
NCT02978651Phase 3Withdrawn
- Sponsor
- Bioprojet
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea (OSA) comparing Pitolisant with Placebo (2 arms). Primary endpoint: Epworth Sleepiness Scale at 52 weeks. Status: withdrawn.
02
Drugs
pitolisant
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT02978651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978651.